Mandibular bone loss: a hidden side effect of botulinum toxin type A injection in masticatory muscles.
DOI:
https://doi.org/10.17126/%25xKeywords:
Botox, masticatory musclesAbstract
Botulinum toxin type A (BoNTA) is the most potent serotype of a group ofneurotoxins produced by obligate anaerobic bacteria Clostridium botulinum. This neurotoxin blocks the release of acetylcholine from the motor neuron, uncoupling the neuromuscular junction that results in a reversible paralysis of skeletal muscles that lasts for 4 – 6 months in humans.1 Commercially available forms of BoNTA (e.g. Botox®, Dysport®, Xeomin®) are increasingly used by dentists worldwide.1 In dentistry, conditions that affect masticator, muscles such as benign masseter hypertrophy and myofascial pain are treated with intramuscular injections of BoNTA,1,2 However, this neurotoxin is not approved for interventions in the masticatory apparatus, according to the US Food and Drug Administration (Allergan Full Prescribing Information for Botox®); as such, its clinical use is off-label.
Downloads
Published
How to Cite
Issue
Section
This is an open-access Journal distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. © 2023.